BIIB News 334.64 08/14/2014 04:44:32 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 334.64 $BIIB

Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - 1 hr 50 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (8) - Europe (19) - France (1) - Germany (8) - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors

Rush University Medical Center Sells AMPYRA(R) Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Business Wire - Tue Aug 12, 7:01AM CDT
DRI Capital Inc. (DRI) and Rush University Medical Center (Rush) announced today that Drug Royalty III, a private equity fund managed by DRI has purchased Rush's royalties relating to worldwide sales of Ampyra(R) for approximately $42 million. Ampyra(R) (dalfampridine) extended release tablets, 10 mg, twice daily, were approved for use in the US in January 2010, and received conditional approval in Europe, where it is known as Fampyra(R), in July 2011. Ampyra is marketed by Acorda Therapeutics, Inc. (Acorda), within the United States, and by Acorda's licensee, Biogen IDEC, internationally.

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.14%
Comtex SmarTrend(R) - Mon Aug 11, 3:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.14% Sell Off
Comtex SmarTrend(R) - Mon Aug 11, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Tech, Health Care Lead Q2 Earnings Beats
at Investor's Business Daily - Mon Aug 11, 12:12PM CDT
Health care and technology stocks have turned in the most Q2 earnings and revenue beats, while the telecom sector has lagged, Merrill Lynch says in a report. Nearly 50 health care companies have reported so far, Merrill Lynch said, and nearly 70%...

Biogen Idec Earnings In Retrospect: Down 4.0% in the Last 19 Days (BIIB)
Comtex SmarTrend(R) - Mon Aug 11, 11:23AM CDT
Two weeks ago on July 23rd, 2014 Biogen Idec (NASDAQ:BIIB) reported earnings and analysts, on average, expected earnings of $2.84 on sales of $2.2 billion. The company actually reported EPS of $3.49 on sales of $2.4 billion, beating EPS estimates by $0.65 and beating revenue estimates by $265.5 million. Since the company's report, shares of Biogen Idec have fallen from $337.60 to $324.05, representing a loss of 4.0% in the past 19 days.

Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
PR Newswire - Thu Aug 07, 12:00PM CDT
Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.

TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta
CNW Group - Thu Aug 07, 9:00AM CDT
Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERATM (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)

Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
PR Newswire - Wed Aug 06, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights.

Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]

Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.

Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.

BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.

Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...

Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 89

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 52

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 30

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 102

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 49

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 26

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 112

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading

Top 5 Most Recently Viewed Articles

Coveo Earns Recognition as Leader in Generative AI Solutions

Updated Category News Views 244

Coveo Achieves AWS Generative AI Competency Coveo, a frontrunner in the field of AI-Relevance, is thrilled to announce its esteemed recognition for achieving the Amazon Web Services (AWS) Generative AI Competency. This designation not only highlights Coveo's exceptional capabilities but also emphasizes its role in helping businesses harness the power of AI to optimize...

Continue Reading
Legal Inquiry Regarding MediaAlpha, Inc. (MAX) Securities Issues

Updated Category News Views 151

Understanding the Securities Investigation of MediaAlpha, Inc. Investors are currently facing a troubling time as MediaAlpha, Inc. (MAX) finds itself under scrutiny. This investigation, brought forth by a prominent law firm, focuses on potential violations of federal securities laws. The significant implication of these allegations has led many investors to seek clarity...

Continue Reading
Rapid Growth in Data Center Liquid Cooling Market Forecasted

Updated Category News Views 159

Overview of the Data Center Liquid Cooling Market The Data Center Liquid Cooling Market has become a crucial focus in modern technology, with its market size projected to rise from USD 2.99 billion to USD 17.28 billion. This significant growth, a Compound Annual Growth Rate (CAGR) of 21.54% from 2024 to 2032, indicates a transitioning landscape in data management...

Continue Reading
Eupraxia Pharmaceuticals Shares Exciting Updates on EoE Trial

Updated Category News Views 327

Eupraxia Pharmaceuticals' Latest Trial Results for EP-104GI Eupraxia Pharmaceuticals Inc. (TSX: EPRX) has reported exciting news regarding its ongoing clinical trial for the treatment of eosinophilic esophagitis (EoE) with EP-104GI. This treatment aims to alleviate symptoms and improve the quality of life for patients suffering from this challenging condition. Highlights...

Continue Reading
Innovative Robotics Solutions Set to Transform Warehousing

Updated Category News Views 253

Revolutionizing Warehouse Operations with Robotics Autonomous forklifts are taking a leap forward by adapting into existing warehouse environments, promising a quick return on investment. The robotics innovator, Riibotics, is poised to present its innovative solutions at RoboBusiness 2025. This event is taking place at the Santa Clara Convention Center, where Riibotics...

Continue Reading